E-resources
Peer reviewed
-
O'Byrne, Kenneth J, Prof; Gatzemeier, Ulrich, MD; Bondarenko, Igor, MD; Barrios, Carlos, MD; Eschbach, Corinna, MD; Martens, Uwe M, MD; Hotko, Yevhen, MD; Kortsik, Cornelius, MD; Paz-Ares, Luis, MD; Pereira, Jose R, MD; von Pawel, Joachim, MD; Ramlau, Rodryg, MD; Roh, Jae-Kyung, Prof; Yu, Chih-Teng, MD; Stroh, Christopher, PhD; Celik, Ilhan, Prof; Schueler, Armin, MS; Pirker, Robert, Prof
The lancet oncology, 08/2011, Volume: 12, Issue: 8Journal Article
Summary Background Findings from the phase 3 FLEX study showed that the addition of cetuximab to cisplatin and vinorelbine significantly improved overall survival, compared with cisplatin and vinorelbine alone, in the first-line treatment of EGFR-expressing, advanced non-small-cell lung cancer (NSCLC). We investigated whether candidate biomarkers were predictive for the efficacy of chemotherapy plus cetuximab in this setting. Methods Genomic DNA extracted from formalin-fixed paraffin-embedded (FFPE) tumour tissue of patients enrolled in the FLEX study was screened for KRAS codon 12 and 13 and EGFR kinase domain mutations with PCR-based assays. In FFPE tissue sections, EGFR copy number was assessed by dual-colour fluorescence in-situ hybridisation and PTEN expression by immunohistochemistry. Treatment outcome was investigated according to biomarker status in all available samples from patients in the intention-to-treat population. The primary endpoint in the FLEX study was overall survival. The FLEX study, which is ongoing but not recruiting participants, is registered with ClinicalTrials.gov , number NCT00148798. Findings KRAS mutations were detected in 75 of 395 (19%) tumours and activating EGFR mutations in 64 of 436 (15%). EGFR copy number was scored as increased in 102 of 279 (37%) tumours and PTEN expression as negative in 107 of 303 (35%). Comparisons of treatment outcome between the two groups (chemotherapy plus cetuximab vs chemotherapy alone) according to biomarker status provided no indication that these biomarkers were of predictive value. Activating EGFR mutations were identified as indicators of good prognosis, with patients in both treatment groups whose tumours carried such mutations having improved survival compared with those whose tumours did not (chemotherapy plus cetuximab: median 17·5 months 95% CI 11·7–23·4 vs 8·5 months 7·1–10·8, hazard ratio HR 0·52 0·32–0·84, p=0·0063; chemotherapy alone: 23·8 months 15·2–not reached vs 10·0 months 8·7–11·0, HR 0·35 0·21–0·59, p<0·0001). Expression of PTEN seemed to be a potential indicator of good prognosis, with patients whose tumours expressed PTEN having improved survival compared with those whose tumours did not, although this finding was not significant (chemotherapy plus cetuximab: median 11·4 months 8·6–13·6 vs 6·8 months 5·9–12·7, HR 0·80 0·55–1·16, p=0·24; chemotherapy alone: 11·0 months 9·2–12·6 vs 9·3 months 7·6–11·9, HR 0·77 0·54–1·10, p=0·16). Interpretation The efficacy of chemotherapy plus cetuximab in the first-line treatment of advanced NSCLC seems to be independent of each of the biomarkers assessed. Funding Merck KGaA.
Author
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.